Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals ...

Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock.

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock. The ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Outperform to Market Perform. There are 2,432 funds or ...

Leerink Partners adjusted their stance on Regeneron (NASDAQ:REGN) Pharmaceuticals, moving the biotech firm's stock from an Outperform to a Market Perform rating. Accompanying this downgrade is a ...

On Tuesday, Biohaven Pharmaceutical Holding (NYSE:BHVN) saw its stock price target increased by Leerink Partners from $55.00 to $60.00. The firm has maintained its Outperform rating on the company's ...